Zosuquidar trihydrochloride

Zosuquidar trihydrochloride is a third-generation P-glycoprotein inhibitor. It is an experimental drug that was developed by Eli Lilly and Company to overcome multidrug resistance in cancer treatment.

Chemistry[edit | edit source]

Zosuquidar trihydrochloride is a synthetic, lipophilic, and highly selective inhibitor of P-glycoprotein. Its chemical name is (R)-6,7-dimethoxy-4-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propoxy)-3-quinazolinamine trihydrochloride.

Mechanism of Action[edit | edit source]

Zosuquidar inhibits the drug efflux pump P-glycoprotein, which is often overexpressed in cancer cells and is associated with multidrug resistance. By inhibiting P-glycoprotein, zosuquidar allows for increased intracellular concentrations of other anticancer drugs, potentially enhancing their efficacy.

Clinical Trials[edit | edit source]

Zosuquidar has been tested in several clinical trials, including a Phase III trial in combination with daunorubicin and cytarabine for the treatment of acute myeloid leukemia (AML). However, the trial did not meet its primary endpoint of improved overall survival.

Side Effects[edit | edit source]

The most common side effects of zosuquidar include nausea, vomiting, and diarrhea. Other side effects may include fatigue, fever, and anemia.

See Also[edit | edit source]

Zosuquidar trihydrochloride Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.